L20- Anticoagulants Flashcards
Intrinsic inhibitors
Antithrombin III
Prostacyclin
Calcium
Heparin mechanism
Inhibits coagulation in vitro and in vivo
Enhances antithrombin III activity
Target factor X - therefore less prothrombin to thrombin
Targets thrombin IIa - less fibrinogen to fibrin
Heparin simultaneously binds to thrombin (IIa) and antithrombin III
Xa inhibition only requires ATIII binding
Unfractionated heparin (45 polysaccharides) onset, half life and delivery
Onset:
Fast onset of action
Half life:
low dose- 30 mins
High dose - 2 hours
Delivery
I.v. Bolus and infusion
Subcutaneous - prophylaxis with low bioavailability
Low molecular weight heparin (15 polysaccharides) examples and mechanism
Dalteparin
Enoxaparin
Fondaparinux - synthetic polysaccharide (5) with longer half life (18 hours)
Does not inactivate thrombin IIa
Inhibits factor Xa specifically by enhancing ATIIIa
Low molecular weight heparin delivery, half life, bioavailability
Delivery:
- subcutaneous
Half life:
- 2+ hours
Bioavailability:
90% +
Pharmacokinetics of unfractionated heparin - metabolism and monitoring
Metabolism:
- dose dependent - protein binding, depolymerisation, desulfation
- 1st and zero order elimination
Monitor: aPTT
Use: severe renal impairment and fine control
Pharmacokinetics of low molecular weight heparin
Dose: predictable Bioavailability: 90% + Metabolism: - rapid liver - slower renal excretion
Monitoring: none
Action: slow onset
Use: most situations
Indications for heparin use (5)
- prevention of thromboembolism
- perioperative prophylaxis
- used during pregnancy as does not cross placenta
- PE or DVT
- ACS
Adverse reactions of heparin
- bruising and bleeding - intracranial, GI, epistaxis, site of injection
(Hepatic and regally impaired, elderly or carcinoma patients at higher risk) - heparin induced thrombocytopenia - antibodies to heparin platelet factor IV complex paradoxically leads to thrombosis as more platelets activated by damaged endothelium
- hyperkaleamia- inhibition of aldosterone secretion
- osteoporosis - rare long term use, higher risk in pregnancy and UFH
Protamine sulphate
Heparin antidote
Positively charged
Forms irreversible inactive complex with heparin
Dissociates heparin from ATIIIa
Warfarin
Vitamin K antagonist
Inhibits activation of vitamin K dependent clotting factors
Inhibits conversion of vitamin K active reduced form
Decreases hepatic synthesis of active clotting factors II, VII,IX and X
Warfarin onset and half life
Delay in onset as active clotting factors need to be metabolised
Half life: 3 to 4 days
Indications for use of warfarin (6)
- PE
- DVT and superficial VT
- Atrial fibrillation with high risk of stroke
- heart valve replacement
- longer term anticoagulation
- If anticoagulation needed immediately give heparin cover
Warfarin pharmacokinetics -bioavailability, variability, pregnancy
Bioavailability: 95% + (good GI absorption)
Variability:
- Functional CYP2C9 polymorphism
- racemic mixture (INR)
- effected by vitamin K intake
Pregnancy:
- crosses placenta - avoid in 1st and 3rd trimester
Warfarin adverse drug reaction and antidote
Bleeding
- epistaxis
- retroperitoneal bleeding
Antidote:
- vitamin K prothrombin complex
- stop warfarin